Inosine pranobex

Identification

Name
Inosine pranobex
Accession Number
DB13156
Type
Small Molecule
Groups
Approved
Description

Inosine pranobex (Isoprinosine or Methisoprinol) is a combination of inosine, acetamidobenzoic acid, and dimethylaminoisopropanol used as an antiviral drug.

Structure
Thumb
Synonyms
  • IAD
  • Inosine acedobene dimepranol
  • Inosine-2-hydroxypropyldimethylammonium 4-acetamidobenzoate (1:3)
  • Inosiplex
  • Isoprinosine
  • Methisoprinol
External IDs
NP-113 / NPT-10381
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImunovirTablet500 mgOralKora Healthcare2000-01-25Not applicableCanada
IsoprinosineTablet500 mgOralNewport Pharmaceuticals International1997-06-052000-02-04Canada
Isoprinosine Tab 500mgTablet500 mgOralSystemed Inc.1993-12-311996-09-10Canada
Isoprinosine Tab 500mgTablet500 mgOralNewport Pharms International Inc.1983-12-311996-09-10Canada
Categories
UNII
W1SO0V223F
CAS number
36703-88-5
Weight
Average: 1115.249
Monoisotopic: 1114.554641092
Chemical Formula
C52H78N10O17
InChI Key
YLDCUKJMEKGGFI-KSIULYHRSA-N
InChI
InChI=1S/C10H12N4O5.3C9H9NO3.3C5H13NO/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18;3*1-6(11)10-8-4-2-7(3-5-8)9(12)13;3*1-5(7)4-6(2)3/h2-4,6-7,10,15-17H,1H2,(H,11,12,18);3*2-5H,1H3,(H,10,11)(H,12,13);3*5,7H,4H2,1-3H3/t4-,6-,7-,10-;;;;3*5-/m1...111/s1
IUPAC Name
tris((2R)-1-(dimethylamino)propan-2-ol); tris(4-acetamidobenzoic acid); 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
SMILES
C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.CC(=O)NC1=CC=C(C=C1)C(O)=O.OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=NC2=C1N=CNC2=O

Pharmacology

Indication

Inosine pranobex is also indicated for mucocutaneous infections due to herpes simplex virus (type 1 and type II) and for treatment of genital warts as adjunctive therapy to podophyllin or carbon dioxide laser.

Associated Conditions
Pharmacodynamics

Works by slowing the growth and spread of the virus in the body. It may also stimulate the immune system in the body, which helps to increase the body's ability to fight these infections.

Mechanism of action

Inosine pranobex stimulates cell-mediated immune processes to viral infections.

Absorption

Rapidly absorbed from GIT

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Via urine

Half life

50 min

Clearance
Not Available
Toxicity

Mouse LD50 (Intravenous ): 1570 mg/kg Muse LD50 (Oral) : 9410mg/kg Mouse LD50 (subcutaneous) ; 2960mg/kg

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Wikipedia [Link]
  2. ChemIDplus [Link]
  3. Pubchem [Link]
External Links
KEGG Drug
D01995
PubChem Compound
131704326
PubChem Substance
347829266
ChemSpider
58829622
Wikipedia
Inosine_pranobex
ATC Codes
J05AX05 — Inosine pranobex
AHFS Codes
  • 08:18.00 — Antivirals
  • 08:18.92 — Miscellaneous Antivirals

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphatic Diseases3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.8 mg/mLALOGPS
logP-1.9ALOGPS
logP-2.5ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)8.93ChemAxon
pKa (Strongest Basic)0.58ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area129.2 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity61.33 m3·mol-1ChemAxon
Polarizability24.6 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Not Available
Direct Parent
Purine nucleosides
Alternative Parents
Glycosylamines / 6-oxopurines / Pentoses / Hypoxanthines / Benzoic acids / Benzoyl derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans
show 14 more
Substituents
Purine nucleoside / Glycosyl compound / N-glycosyl compound / 6-oxopurine / Pentose monosaccharide / Purinone / Hypoxanthine / Imidazopyrimidine / Benzoic acid or derivatives / Purine
show 38 more
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on December 03, 2016 17:28 / Updated on July 19, 2018 17:49